RxDoctor Payments Data

Richard Zorowitz, MD

Physical Medicine & Rehabilitation · Washington, DCNPI 1568493237

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,287 of the $57,058 with a category attached, or 65.3%. 12 manufacturers reported payments, led by Ipsen Innovation at 33.3% of the total. Reporting peaked in 2024 at $23,607 and has fallen 60.8% since, to $9,251 in 2025. Among physical medicine & rehabilitation clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,058in general payments, 2019–2025

Across 55 payments — averaging $1037.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Innovation$19K
  • Ipsen Pharma SAS$17K
  • SPR Therapeutics, Inc$7K
  • Ipsen Biopharmaceuticals, Inc$6K
  • Ipsen Biopharm Limited$4K
  • AbbVie$3K
  • plus $731 from 6 others
$499,877in research payments, 2019–2025

Across 200 payments — averaging $2499.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ipsen Pharma SAS$419K
  • AbbVie$31K
  • Sunovion Pharmaceuticals Inc.$29K
  • Ipsen Innovation$21K

What the payments were for

  • Consulting fees$37,28765%
  • Speaking & faculty fees$1,4202%
  • Travel & lodging$16,55629%
  • Food & beverage$1,7963%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Innovation4$18,995
Ipsen Pharma SAS8$17,025
SPR Therapeutics, Inc21$6,681
Ipsen Biopharmaceuticals, Inc11$6,038
Ipsen Biopharm Limited1$4,260
AbbVie2$3,328
Merz Pharmaceuticals, LLC3$258
Microtransponder, Inc.1$190
Merz North America, Inc.1$124
Revance Therapeutics, Inc.1$122
AstraZeneca1$20
Smith+Nephew1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,058 in reported general payments places this provider in the 95th percentile of 41 physical medicine & rehabilitation providers in District of Columbia.

See all physical medicine & rehabilitation providers in District of Columbia

Medicare billing

Part B allowed, 2024
$78,944
Medicare patients
178
Services billed
970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DysportAbobotulinumtoxina13$24,576
BotoxOnabotulinumtoxina14$20,828
Dantrolene Sodium25$4,370
Gabapentin98$2,872
Baclofen66$2,473
AmantadineAmantadine Hcl22$2,452
Levetiracetam13$1,815
Duloxetine Hcl35$1,222
Midodrine Hcl15$907
Pregabalin30$776
Fentanyl12$725
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$658
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen28$608
Methadone Hcl12$595
Methylphenidate ErMethylphenidate Hcl22$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ipsen Biopharmaceuticals, IncDysport$6,038$24,57613 claims
AbbVieBotox$3,328$20,82814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 physical medicine & rehabilitation providers in District of Columbia.

Other physical medicine & rehabilitation in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →